Yu Jun Wong

Has grant

National University of Singapore (NUS)

Singapore

Research Interests

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Baveno_VII criteria to predict liver decompensation in cACLD patients: a competing risk analysis

Open Date:

Close Date:

Grant: Close

The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients

Open Date:

Close Date:

Grant: Close

Integrated care for chronic liver disease and portal-hypertension related complications

Open Date:

Close Date:

Grant: Close

Master of Clinical Investigator (MCI)

Open Date:

Close Date:

Articles (10)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (3)

Nicola Coppola

ITALY

View details

Charles Chin Han Lew

Adjunct Assistant Professor

SINGAPORE

View details

Karn Wijarnpreecha

Associate Clinical Professor

University of Arizona College of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Yu Jun Wong

Research Interests

Contact this professor

Recent Grants

Articles (10)

Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis

Benefits and harm of probiotics and synbiotics in adult critically ill patients. A systematic review and meta-analysis of randomized controlled trials with trial sequential analysis

Human Albumin Infusion for the Management of Liver Cirrhosis and Its Complications: An Overview of Major Findings from Meta-analyses

Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients

Correspondence on Editorial regarding “Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients”

Non-alcoholic fatty liver disease screening in type 2 diabetes mellitus: A cost-effectiveness and price threshold analysis

A Novel SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102): An International Multicenter Cohort Study

ABC: a novel algorithm to stratify decompensation risk in patients with compensated advanced chronic liver disease (CHESS2108): an international, multicenter cohort study

Development and validation of a machine learning–based model for varices screening in compensated cirrhosis (CHESS2001): an international multicenter study

Clinical trial: seven‐day vonoprazan‐ versus 14‐day proton pump inhibitor‐based triple therapy for first‐line <i>Helicobacter pylori</i> eradication

Collaborators (3)

Nicola Coppola

Charles Chin Han Lew

Karn Wijarnpreecha

Make your next move.